Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Commercially available ovoid tubes for gynecological applications used in conjunction with the microSelectron-HDR (Nucletron International B.V., Waardegelder 1, 3905 TH Veenendaal, The Netherlands) for 192Ir sources, allow for shielding. Publications concerning the transmission properties of these 4.5-mm thick stainless steel (AISI number 303/304) shielding segments are scarce and not compatible for implementation in treatment planning. Therefore the effect of shielding on dose distribution is unknown. The effective transmission factor has been measured and implemented in the planning computations. Screening efficacy was evaluated on 20 actual treatment plans, analyzing dose reduction to critical tissue and comparing dose distribution in planes relevant for this particular application. Due to high transmission (effective transmission factor = 0.85), stainless steel screening segments only provide low, local dose reductions of maximum 15%. A new approach with regard to optimization and source configuration is needed to reduce dose to vulnerable tissue, exploiting the screening segments to a maximum extent. Better shielding, especially at the midline (plane bisecting the ovoids) could be expected by using shielding segments with other geometrical characteristics.

Original publication




Journal article


Med Phys

Publication Date





1677 - 1684


Biophysical Phenomena, Biophysics, Brachytherapy, Female, Humans, Iridium Radioisotopes, Radiation Protection, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted, Stainless Steel, Uterine Cervical Neoplasms